Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells 4,370 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $12.43 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.13 and a 1 year high of $18.07. The firm has a market cap of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46. The stock has a fifty day moving average price of $12.37 and a two-hundred day moving average price of $13.47.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at about $27,000. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares in the last quarter. Quest Partners LLC grew its position in Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after buying an additional 9,603 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

DAWN has been the topic of several analyst reports. Bank of America dropped their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.